Benzinga | Aug 10, 2020 04:36PM EDT

Equillium Announces Positive Interim Data With Itolizumab In Acute GVHD Study; Says Complete Response Observed In Five Of Seven Patients In First Two Dose Cohorts

Complete response observed in five of seven patients in first two dose cohorts



COVID-19 Pre-IND meeting request and briefing package submitted to the FDA

LA JOLLA, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (NASDAQ:EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced positive interim data from the first two cohorts of the Phase 1b open label, dose escalation portion of the EQUATE study of itolizumab in acute graft-versus-host disease (aGVHD). Across the first two dose cohorts itolizumab has been generally well tolerated to date, and five of seven patients achieved a complete response (CR) by Day 29. Additionally, Equillium has submitted a request to the U.S. Food and Drug Administration (FDA) for a Pre-Investigational New Drug (Pre-IND) meeting to review its proposal to initiate a global randomized controlled clinical trial to study itolizumab in hospitalized patients with COVID-19.